treosulfan + fludarabine + cyclophosphamide + allogeneic hematopoietic stem cell transplantation

This therapeutic regimen, designated as protocol MT2025-35, is an allogeneic hematopoietic stem cell transplantation (allo-HSCT) procedure utilizing a specific reduced-intensity conditioning (RIC) and graft-versus-host disease (GVHD) prophylaxis strategy. Developed by the Masonic Cancer Center at the University of Minnesota, the regimen involves conditioning with treosulfan (a bifunctional alkylating agent) and fludarabine (a purine analog antimetabolite), often supplemented with low-dose total body irradiation (TBI). Following the infusion of allogeneic stem cells from related or unrelated donors, patients receive high-dose post-transplant cyclophosphamide (PTCy), tacrolimus, and mycophenolate mofetil (MMF) to prevent GVHD. This approach is designed to treat high-risk hematological malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other acute leukemias, by facilitating a curative graft-versus-leukemia effect while minimizing the toxicities associated with traditional myeloablative conditioning.

Other names

Treo/Flu with PTCy for Hematological DiseasesStem Cell InfusionReduced Intensity Conditioning Treosulfan and Fludarabine with Post-Transplant Cytoxan